Lichen planus drugs re-purposing as potential anti COVID-19 therapeutics through molecular docking and molecular dynamics simulation approach
Background and Aim: The present study intends to investigate COVID-19 by targeting their main proteins with 17 selected drugs used for treating Oral Lichen Planus (OLP) which is a chronic mucocutaneous disorder. Here, an attempt is made to gain better insight into the structure of various drugs targeting specific proteins which will be helpful in developing drugs useful for therapeutic and preventive measures.
Method: In silico studies, molecular docking and molecular dynamic simulations were performed to repurpose the therapeutic drugs (n = 17) which were used to treat OLP against COVID-19. In addition, the maximum binding affinities of the key protein spike glycoprotein, main-protease (Mpro) of coronavirus, and Angiotensin-Converting Enzyme-2 (ACE-2) in the human body were evaluated with the selected drugs.
Results: Epigallocatechin-3-gallate (EGCG) showed the highest docking values among the drugs selected for repurposing. Among the target proteins, EGCG has shown maximum binding affinity with ACE-2 receptor. Further, according to the molecular dynamic simulation studies, EGCG has shown the least conformational fluctuations with Mpro.
Conclusion: EGCG can be a potential inhibitor drug which can bind with ACE-2 receptor thus inhibiting the interaction of mainly Mpro protein and spike glycoprotein of SARS-CoV-2.
Relevance for Patients: EGCG, a natural compound shows antiviral potential having considerably high affinity and stability with SARS-CoV-2. It might be further employed as a lead drug against selective inhibitors of SARS-CoV-2 for the therapeutic management of COVID-19 patients after necessary clinical trials.
[1] Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19); 2020. Available from: https://ourworldindata.org/coronavirus [Last accessed on 2021 Dec 24].
[2] Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus Disease 2019-COVID-19. Clin
Microbiol Rev 2020;33:e00028.
[3] Jairajpuri DS, Hussain A, Nasreen K, Mohammad T, Anjum F, Rehman MT, et al. Identification of Natural
Compounds as Potent Inhibitors of SARS-CoV-2 Main Protease Using Combined Docking and Molecular Dynamics Simulations. Saudi J Biol Sci 2021;28:2423-31.
[4] Zhang J, Zhou G. Green tea Consumption: An Alternative Approach to Managing Oral Lichen Planus. Inflamm Res 2012;61:535-9.
[5] Pratyush S, Pratik P, Raghu AR, Ankur KS, Monica S. Current Assessments Regarding the Pathogenesis and
Treatment Strategies of Oral Lichen Planus a Review. Asian Pac J Health Sci 2014;1:96-103.
[6] Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-Converting Enzyme 2:
SARS-CoV-2 Receptor and Regulator of the ReninAngiotensin System. Circ Res 2020;126:1456-74.
[7] Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A Novel Angiotensin-onverting
Enzyme-related Carboxypeptidase (ACE-2) Converts Angiotensin I to Angiotensin 1-9. Circ Res 2000;87:E1-9.
[8] Wang K, Gheblawi M, Oudit GY. Angiotensin Converting Enzyme 2: ADouble-Edged Sword. Circulation. 2020;142:426-8.
[9] Kuan TC, Chen MY, Liao YC, Ko L, Hong YH, Yen CY, et al. Angiotensin II Downregulates ACE-2-Mediated Enhancement of MMP-2 Activity in Human Cardiofibroblasts. Biochem Cell Biol 2013;91:435-42.
[10] Steagall WK, Stylianou M, Pacheco-Rodriguez G, Moss J. Angiotensin-Converting Enzyme Inhibitors May Affect Pulmonary Function in Lymphangioleiomyomatosis. JCI Insight 2019;4:e126703.
[11] Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and Ligand Preparation: Parameters,
Protocols, and Influence on Virtual Screening Enrichments. J Comput Aided Mol Des 2013;27:221-34.
[12] Halgren TA. Identifying and Characterizing Binding Sites and Assessing Druggability. J Chem Inf Mod 2009;49:377-38.
[13] Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra Precision
Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-ligand Complexes.
J Med Chem 2006;49:6177-96.
[14] Chakraborty C, Sharma AR, Mallick B, Bhattacharya M, Sharma G, Lee SS. Evaluation of Molecular Interaction, Physicochemical Parameters and Conserved Pattern of SARS-CoV-2 Spike RBD and hACE-2: In silico and Molecular Dynamics Approach. Eur Rev Med Pharmacol Sci 2021;25:1708-23.
[15] Almeida-Neto FW, Matos MG, Marinho EM, MarinhoMM, de Menezes RR, Sampaio TL, et al. In silico Study of the Potential Interactions of 4’-Acetamidechalcones with Protein Targets in SARS-CoV-2. Biochem Biophys Res Commun 2021;537:71-7.
[16] Liang J, Pitsillou E, Karagiannis C, Darmawan KK, Ng K, Hung A, et al. Interaction of the Prototypical α-ketoamide Inhibitor with the SARS-CoV-2 Main Protease Active Site in silico: Molecular Dynamic Simulations Highlight the Stability of the Ligand-protein Complex. Comput Biol Chem 2020;2020:107292.
[17] Hirshman SP, Whitson JC. Steepest-descent Moment Method for Three-dimensional Magnetohydrodynamic Equilibria. Phys Fluids 1983;26:3553-68.
[18] Hess B, Bekker H, Berendsen HJ, Fraaije JG. LINCS: A Linear Constraint Solver for Molecular Simulations.
J Comput Chem 1997;18:1463-72.
[19] Cheatham TE, Miller JL, Fox T, Darden TA, Kollman PA. Molecular Dynamics Simulations on Solvated
Biomolecular Systems: The Particle Mesh Ewald Method Leads to Stable Trajectories of DNA, RNA and Proteins.
J Am Chem Soc 1995;117:4193-4.
[20] Rosa SG, Santos WC. Clinical Trials on Drug Repositioning for COVID-19 Treatment. Rev Panam Salud Publica 2020;44:e40.
[21] Maurya VK, Kumar S, Prasad AK, Bhatt ML, Saxena SK. Structure-based Drug Designing for Potential Antiviral Activity of Selected Natural Products from Ayurveda against SARS-CoV-2 Spike Glycoprotein and its Cellular Receptor. Virusdisease 2020;31:179-93.
[22] Granja A, Frias I, Neves AR, Pinheiro M, Reis S. Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems. Biomed Res Int 2017;2017:5813793.
[23] Pae M, Ren Z, Meydani M, Shang F, Meydani SN, Wu D. Epigallocatechin-3-Gallate Directly Suppresses T Cell Proliferation through Impaired IL-2 Utilization and Cell Cycle Progression. J Nutr 2010;140:1509-15.
[24] Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, et al. Proteasome Inhibition Suppresses Essential Immune Functions of Human CD4+ T Cells. Immunology 2008;124:234-46.
[25] Kawai K, Tsuno NH, Kitayama J, Okaji Y, Yazawa K, Asakage M, et al. Epigallocatechin Gallate Attenuates
Adhesion and Migration of CD8+ T cells by Binding to CD11b. J Allergy Clin Immunol 2004;113:1211-7.
[26] Ho YC, Yang SF, Peng CY, Chou MY, Chang YC. Epigallocatechin-3-gallate Inhibits the Invasion of Human
Oral Cancer Cells and Decreases the Productions of Matrix Metalloproteinases and Urokinase-plasminogen Activator. J Oral Pathol Med 2007;36:588-93.
[27] Demeule M, Brossard M, Pagé M, Gingras D, Béliveau R. Matrix Metalloproteinase Inhibition by Green Tea
Catechins. Biochim Biophys Acta 2000;1478:51-60.